Butyricicoccus spp. based Microbiome Therapeutic Research Services
In the rapidly evolving landscape of the human microbiome, the focus is shifting from general diversity to specific, high-functionality keystone species. Among these, the genus Butyricicoccus has emerged as a critical player in maintaining intestinal homeostasis. As a specialized Contract Research Organization (CRO), Creative Biolabs provides a dedicated Butyricicoccus spp. Based Microbiome Therapeutic Research Service. We assist pharmaceutical companies, biotech startups, and academic institutions in navigating the complex journey from strain isolation to preclinical validation. Our goal is to help you harness the potent anti-inflammatory and barrier-protecting properties of these bacteria to develop novel Live Biotherapeutic Products (LBPs).
Why Butyricicoccus? The Science of Butyrate
While Faecalibacterium prausnitzii has long been the poster child for butyrate production, Butyricicoccus species offer distinct advantages in terms of abundance, specific metabolic pathways, and potentially superior stability during manufacturing. Butyricicoccus is a clostridial cluster IV genus, strictly anaerobic, and a prolific producer of butyrate. Butyrate is not merely a metabolite; it is a signaling molecule essential for colonic health. The primary mechanism of action for this genus lies in its exceptional ability to convert dietary fibers into butyrate. Butyrate is not merely a metabolite; it is the primary energy source for colonocytes (colon cells) and a potent histone deacetylase (HDAC) inhibitor. By fueling the gut lining and regulating gene expression, Butyricicoccus spp. strengthen the mucosal barrier and prevent the translocation of pathogens and toxins into the bloodstream.
Explore Our Specialized Strains
We offer specialized research modules for the following key species. Click below to explore detailed technical data and specific service workflows for each.
A flagship butyrate producer often depleted in patients with inflammatory bowel disease. Our service focuses on characterizing its robust anti-inflammatory properties and optimizing anaerobic fermentation protocols to ensure high viability for next-generation therapeutic applications.
Isolated from the human gut, this species represents a promising candidate for targeted colonization. We offer comprehensive genomic profiling and interaction analysis to evaluate its efficacy in modulating host epithelial barrier integrity and immune responses.
Originally identified in swine, this species offers unique insights into veterinary microbiome applications and comparative host-microbe interactions. Our research platform explores its metabolic pathways and potential cross-species utility in maintaining intestinal homeostasis.
Our Comprehensive Service Modules
Developing a strict anaerobe into a drug product is fraught with technical challenges. We provide an end-to-end solution.
Understanding the strain at a molecular level is a regulatory necessity.
Whole Genome Sequencing (WGS): Assembly and annotation of genomes to identify functional gene clusters (e.g., butyryl-CoA: acetate CoA-transferase gene).
Metabolomics: Quantitative analysis of Short-Chain Fatty Acids (SCFAs) using GC-MS to verify therapeutic potency.
Safety Assessment: Screening for antimicrobial resistance (AMR) genes and virulence factors to meet guidelines.
Preclinical Validation
We offer robust in vitro and in vivo models to prove efficacy.
In Vitro Co-culture: Analyzing the interaction between Butyricicoccus and human Caco-2/HT-29 cell lines to measure barrier function (TEER) and cytokine suppression (IL-8, TNF-α).
In Vivo Disease Models: Testing efficacy in DSS-induced colitis, TNBS colitis, and high-fat diet-induced obesity mouse models.
Products Available
Accelerate your internal research with our ready-to-use biological reagents.
This product contains high-quality, intact genomic DNA isolated from Butyricicoccus pullicaecorum Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research indicates that the abundance of Butyricicoccus is negatively correlated with several chronic conditions. Our services aim to restore this balance.
Inflammatory Bowel Disease (IBD)
Patients with Ulcerative Colitis and Crohn's Disease consistently show a reduction in B. pullicaecorum. We help develop LBPs designed to recolonize the mucin layer and reduce mucosal inflammation.
Metabolic Syndrome
By influencing gut barrier integrity, Butyricicoccus can reduce metabolic endotoxemia (LPS leakage), which is a driver of insulin resistance and obesity. We assist in screening strains for metabolic regulation capabilities.
The Gut-Brain Axis
Emerging evidence suggests that butyrate can cross the blood-brain barrier or influence vagal nerve signaling. We provide exploratory services for neuro-inflammatory indications.
Why Partner with Us?
Anaerobic Expertise
We possess state-of-the-art anaerobic chambers and fermentation units specifically calibrated for Clostridial cluster IV species.
Regulatory Ready
Our data packages are formatted to support IND (Investigational New Drug) applications.
Customizable Assays
We do not believe in "cookie-cutter" science. We design assays based on your specific therapeutic hypothesis.
Scalability
From bench-top research to pilot-scale fermentation, we help you assess the manufacturability of your strain early in the process.
Accelerate Your Microbiome Pipeline Today
The era of generalized gut health is ending; the era of targeted functionality has begun. Butyricicoccus represents a frontier in this evolution—a potent, naturally occurring therapeutic candidate capable of healing the gut from within. However, the path from a petri dish to a pill is fraught with technical challenges, particularly regarding anaerobic stability and mechanism validation. By partnering with Creative Biolabs, you gain more than a service provider; you gain a scientific co-pilot. We provide the technical scaffolding required to elevate your Butyricicoccus research from concept to clinical candidate. Let us handle the complexities of anaerobic microbiology so you can focus on the breakthrough.
How difficult is it to scale up Butyricicoccus production compared to Lactobacilli?
Butyricicoccus species are strict anaerobes and more sensitive to oxygen and shear stress than Lactobacillus. Our process development team specializes in optimizing cryoprotectants and lyophilization cycles specifically for these sensitive organisms to ensure commercial viability.
Can you handle Intellectual Property (IP) generation?
Absolutely. As a CRO, we operate on a fee-for-service model. All strains isolated, data generated, and IP developed during the project belong entirely to the client. We sign strict NDAs to protect your proprietary information.
Do you offer safety toxicity studies?
Yes. We conduct acute and repeated-dose oral toxicity studies in rodents, complete with translocation analysis, to demonstrate the safety of the probiotic strain.
Specific strain identification is required. Can you distinguish between closely related species?
Yes. We utilize Average Nucleotide Identity (ANI) analysis and 16S rRNA gene full-length sequencing to definitively distinguish between B. pullicaecorum, B. faecihominis, and other closely related phylotypes.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
